A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 After Repeated Doses in Schizophrenic Patients. Relationship With Pharmacokinetics and Efficacy Readouts.

Trial Profile

A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 After Repeated Doses in Schizophrenic Patients. Relationship With Pharmacokinetics and Efficacy Readouts.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2012

At a glance

  • Drugs Risperidone (Primary)
  • Indications Psychotic disorders; Schizophrenia
  • Focus Biomarker; Pharmacodynamics
  • Acronyms SPECT
  • Most Recent Events

    • 12 Oct 2008 Trial phase changed from II to I as reported by ClinicalTrials.gov
    • 12 Oct 2008 Status changed from discontinued to completed.
    • 26 Oct 2007 Status changed from in progress to discontinued
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top